Skip to main content

Advertisement

SpringerLink
Log in

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

  • Original Article
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG) small-animal positron emission tomography (PET) in the middle cerebral artery occlusion (MCAO) rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline (controls). Weekly PET imaging and neurologic function tests showed that the 18F-FDG accumulation in the bevacizumab group was similar to that in the controls during the first 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not influence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tang Z, Zhou T, Luo Y, Xie C, Huo D, Tao L, et al. Risk factors for cerebrovascular disease mortality among the elderly in Beijing: a competing risk analysis. PLoS One 2014, 9: e87884.

    Article  PubMed  PubMed Central  Google Scholar 

  2. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med 2005, 353: 1124–1134.

    Article  PubMed  CAS  Google Scholar 

  3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009, 8: 355–369.

    Article  PubMed  Google Scholar 

  4. Pappachan J, Kirkham FJ. Cerebrovascular disease and stroke. Arch Dis Child 2008, 93: 890–898.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985, 64: 16–35.

    Article  CAS  Google Scholar 

  6. Kim SJ, Park JH, Lee MJ, Park YG, Ahn MJ, Bang OY. Clues to occult cancer in patients with ischemic stroke. PLoS One 2012, 7: e44959.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3: 391–400.

    Article  PubMed  CAS  Google Scholar 

  8. The FDA approves drugs for colorectal cancer, lung cancer. FDA Consum 2007, 41: 5.

  9. Cloughesy T. FDA accelerated approval benefits glioblastoma. Lancet Oncol 2010, 11: 1120.

    Article  PubMed  Google Scholar 

  10. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010, 15: 104–111.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol 2013, 31: 3592–3599.

    Article  PubMed  Google Scholar 

  12. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99: 1232–1239.

    Article  PubMed  Google Scholar 

  13. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008, 10: 86–91.

    Article  PubMed  Google Scholar 

  14. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009, 39: 826–834.

    Article  PubMed  CAS  Google Scholar 

  15. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975, 16: 210–224.

    PubMed  CAS  Google Scholar 

  16. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978, 19: 1154–1161.

    PubMed  CAS  Google Scholar 

  17. Tatsch K. Positron emission tomography in diagnosis and differential diagnosis of Parkinson’s disease. Neurodegener Dis 2010, 7: 330–340.

    Article  PubMed  Google Scholar 

  18. Bohnen NI, Frey KA. The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am 2003, 13: 791–803.

    Article  PubMed  Google Scholar 

  19. Kim YK, Lee DS, Lee SK, Kim SK, Chung CK, Chang KH, et al. Differential features of metabolic abnormalities between medial and lateral temporal lobe epilepsy: quantitative analysis of (18)F-FDG PET using SPM. J Nucl Med 2003, 44: 1006–1012.

    PubMed  Google Scholar 

  20. Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol 2004, 6: 239–269.

    Article  PubMed  Google Scholar 

  21. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008, 190: W365–369.

    Article  PubMed  Google Scholar 

  22. Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, et al. Amyloid imaging with carbon 11-labeled Pittsburgh Compound B for traumatic brain injury. JAMA Neurol 2014, 71: 23–31.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cash SS, Larvie M, Dalmau J. Case records of the Massachusetts General Hospital. Case 34-2011: A 75-year-old man with memory loss and partial seizures. N Engl J Med 2011, 365: 1825–1833.

    Article  PubMed  CAS  Google Scholar 

  24. Singhal T. Positron emission tomography applications in clinical neurology. Semin Neurol 2012, 32: 421–431.

    PubMed  Google Scholar 

  25. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000, 97: 9226–9233.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Shalhoub J, Oskrochi Y, Davies AH, Owen DR. Clinical assessment of carotid atherosclerosis inflammation by positron emission tomography. Curr Mol Med 2013, 13: 1646–1652.

    Article  PubMed  CAS  Google Scholar 

  27. Wang J, Chao F, Han F, Zhang G, Xi Q, Li J, et al. PET demonstrates functional recovery after transplantation of induced pluripotent stem cells in a rat model of cerebral ischemic injury. J Nucl Med 2013, 54: 785–792.

    Article  PubMed  CAS  Google Scholar 

  28. Curtin LI, Grakowsky JA, Suarez M, Thompson AC, DiPirro JM, Martin LB, et al. Evaluation of buprenorphine in a postoperative pain model in rats. Comp Med 2009, 59: 60–71.

    PubMed  CAS  PubMed Central  Google Scholar 

  29. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995, 26: 627–634; discussion 635.

    CAS  Google Scholar 

  30. Bang OY, Seok JM, Kim SG, Hong JM, Kim HY, Lee J, et al. Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol 2011, 7: 53–59.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chowdhary S, Chamberlain M. Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother 2013, 13: 937–949.

    Article  PubMed  CAS  Google Scholar 

  32. Wang CJ, Huang KE, Sun YC, Yang YJ, Ko JY, Weng LH, et al. VEGF modulates angiogenesis and osteogenesis in shockwave-promoted fracture healing in rabbits. J Surg Res 2011, 171: 114–119.

    Article  PubMed  CAS  Google Scholar 

  33. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010, 51: 2835–2842.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lu Y, Zhou N, Huang X, Cheng JW, Li FQ, Wei RL, et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol 2014, 7: 1–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Ishrat T, Pillai B, Soliman S, Fouda AY, Kozak A, Johnson MH, et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. Mol Neurobiol 2014.

    Google Scholar 

  36. Li YN, Pan R, Qin XJ, Yang WL, Qi Z, Liu W, et al. Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression. J Neurochem 2014, 129: 120–129.

    Article  PubMed  CAS  Google Scholar 

  37. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007, 27: 1196–1200.

    Article  PubMed  Google Scholar 

  38. Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol 2011, 5: 697–704.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China

    Ying Dong, Jianjuan Ma & Xuexin He

  2. Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China

    Fahuan Song & Mei Tian

  3. Zhejiang University Medical PET Center, Hangzhou, 310009, China

    Fahuan Song & Mei Tian

  4. Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Hangzhou, 310009, China

    Fahuan Song & Mei Tian

  5. Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, 310009, China

    Fahuan Song & Mei Tian

  6. Department of Zoology, Faculty of Science, Kafr El Sheikh University, Kafr el-Sheikh, Egypt

    Said Amer

  7. Department of Pathology, The Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China

    Weizhong Gu

Authors
  1. Ying Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fahuan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianjuan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuexin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Said Amer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weizhong Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mei Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei Tian.

Additional information

These authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, Y., Song, F., Ma, J. et al. Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury. Neurosci. Bull. 30, 838–844 (2014). https://doi.org/10.1007/s12264-014-1470-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-014-1470-z

Keywords

Search

Navigation